Still avoiding the question

The TeGenero drug trial is complete, and an ongoing study is examing whether trial requirements should be changed. But, asks Nuala Moran, should the trial ever have been approved?

Investors head for the central nervous system

Advances in neuroscience are opening up the treatment options for central nervous system diseases - at the same time as the ageing population is increasing the market for these products.